423 related articles for article (PubMed ID: 25484037)
1. Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.
Peng K; Xu K; Liu L; Hendricks R; Delarosa R; Erickson R; Budha N; Leabman M; Song A; Kaur S; Fischer SK
MAbs; 2014; 6(6):1500-8. PubMed ID: 25484037
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.
Baruch A; Luca D; Kahn RS; Cowan KJ; Leabman M; Budha NR; Chiu CPC; Wu Y; Kirchhofer D; Peterson A; Davis JC; Tingley WG
Clin Cardiol; 2017 Jul; 40(7):503-511. PubMed ID: 28326559
[TBL] [Abstract][Full Text] [Related]
3. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
4. Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.
Budha NR; Leabman M; Jin JY; Wada DR; Baruch A; Peng K; Tingley WG; Davis JD
AAPS J; 2015 Jul; 17(4):881-90. PubMed ID: 25823668
[TBL] [Abstract][Full Text] [Related]
5. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement.
Henne KR; Ason B; Howard M; Wang W; Sun J; Higbee J; Tang J; Matsuda KC; Xu R; Zhou L; Chan JC; King C; Piper DE; Ketchem RR; Michaels ML; Jackson SM; Retter MW
J Pharmacol Exp Ther; 2015 Apr; 353(1):119-31. PubMed ID: 25653417
[TBL] [Abstract][Full Text] [Related]
6. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
Schiele F; Park J; Redemann N; Luippold G; Nar H
J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
Shen T; James DE; Krueger KA
Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
9. Selection and characterization of human PCSK9 antibody from phage displayed antibody library.
Cao Y; Yang H; Zhou X; Mao H; Gao T; Hu Z; He L; Pan F; Guo Z
Biochem Biophys Res Commun; 2015 Aug; 463(4):712-8. PubMed ID: 26056005
[TBL] [Abstract][Full Text] [Related]
10. Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function.
Gelzleichter TR; Halpern W; Erwin R; Baruch A; Leabman M; Forrest AS; Satterwhite CM; Peng K; Chilton J; Stevens D
Toxicol Sci; 2014 Aug; 140(2):470-80. PubMed ID: 24848798
[TBL] [Abstract][Full Text] [Related]
11. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
[TBL] [Abstract][Full Text] [Related]
12. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.
Yoon CH; Watson K
Ann Pharmacother; 2014 Feb; 48(2):238-49. PubMed ID: 24259646
[TBL] [Abstract][Full Text] [Related]
13. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin.
de Dios K; Manibusan A; Marsden R; Pinkstaff J
J Immunol Methods; 2013 Oct; 396(1-2):1-7. PubMed ID: 23933323
[TBL] [Abstract][Full Text] [Related]
14. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies.
Wang SJ; Wu ST; Gokemeijer J; Fura A; Krishna M; Morin P; Chen G; Price K; Wang-Iverson D; Olah T; Weiner R; Tymiak A; Jemal M
Anal Bioanal Chem; 2012 Jan; 402(3):1229-39. PubMed ID: 22130720
[TBL] [Abstract][Full Text] [Related]
15. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.
Koren MJ; Scott R; Kim JB; Knusel B; Liu T; Lei L; Bolognese M; Wasserman SM
Lancet; 2012 Dec; 380(9858):1995-2006. PubMed ID: 23141812
[TBL] [Abstract][Full Text] [Related]
17. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
18. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
19. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
20. Plasma PCSK9 measurement by liquid chromatography-Tandem mass spectrometry and comparison with conventional ELISA.
Croyal M; Fall F; Krempf M; Thédrez A; Ouguerram K; Ferchaud-Roucher V; Aguesse A; Billon-Crossouard S; Mata P; Alonso R; Lambert G; Nobécourt E
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Feb; 1044-1045():24-29. PubMed ID: 28064066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]